Skip to main content
. 2012 Nov 12;15(3):264–271. doi: 10.1111/dom.12026

Figure 1.

Figure 1

Changes in glycaemic control and body weight over 52 weeks. Patients (Intent-to-Treat, ITT population; N = 675) treated with exenatide once weekly (ExQW) for up to 52 weeks experienced reductions [mean change (SE)] from baseline in (A) HbA1c, (B) fasting blood glucose (FBG), and (C) body weight. (D) The majority of ITT patients experienced reductions in both HbA1c and body weight.